Plus   Neg

Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates

Regeneron Pharmaceuticals (REGN) revealed a profit for its second quarter that increased from last year.

The company's bottom line totaled $897.3 million, or $7.61 per share. This compares with $193.1 million, or $1.68 per share, in last year's second quarter.

Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $854.4 million or $7.16 per share for the period.

Analysts had expected the company to earn $5.98 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 23.4% to $1.95 billion from $1.58 billion last year.

Regeneron Pharmaceuticals earnings at a glance:

-Earnings (Q2): $854.4 Mln. vs. $690.0 Mln. last year.
-EPS (Q2): $7.16 vs. $6.02 last year.
-Analysts Estimate: $5.98
-Revenue (Q2): $1.95 Bln vs. $1.58 Bln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT